What's the price of Novo Nordisk A/S (NVO) stock?
Since then, NVO stock has increased by 78.4% and is now trading at $103.25. View which stocks have been most impacted by COVID-19. When is Novo Nordisk A/S's next earnings date? Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, May 4th 2022. How were Novo Nordisk A/S's earnings last quarter?
Who holds Novo Nordisk A/S'Stock?
Only 0.07% of the stock of Novo Nordisk A/S is held by insiders. Only 5.59% of the stock of Novo Nordisk A/S is held by institutions. Earnings for Novo Nordisk A/S are expected to grow by 6.31% in the coming year, from $3.17 to $3.37 per share.
What does a hold rating mean for Novo Nordisk A/S (NVO)?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares. View analyst ratings for Novo Nordisk A/S or view top-rated stocks.
What are Wall Street's target prices for Novo Nordisk A/S's Stock?
14 Wall Street analysts have issued twelve-month target prices for Novo Nordisk A/S's shares. Their forecasts range from $592.00 to $592.00. On average, they anticipate Novo Nordisk A/S's stock price to reach $592.00 in the next year.
See more
Is Novo Nordisk A good buy?
Valuation metrics show that Novo Nordisk AS may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of NVO, demonstrate its potential to outperform the market. It currently has a Growth Score of A.
Is NVO a good stock?
Good Rank and Rising Estimates: Novo Nordisk currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novo Nordisk's earnings has risen from $3.32 per share to $3.33 per share for 2022 over the past 60 days.
Is NVO an ADR?
Range: 2022-07-01 09:23:42 to 2022-07-01 20:05:17....Novo Nordisk A/S ADR.Volume1.47MEPS (TTM)$3.36P/E Ratio (TTM)33.25Dividend Yield1.00%Latest Dividend$0.747 more rows
How many employees does Novo Nordisk have?
With U.S. headquarters in New Jersey and production and research facilities in six states, Novo Nordisk employs nearly 6,000 employees throughout the country.
Can I buy Novo Nordisk shares?
Ready to invest? To buy shares in Novo-Nordisk A/S, you'll need to have an account. Try our handy filter to explore the different options.
Why did Novo Nordisk share price fall?
COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO) shares fell as much as 16% on Monday after the Danish drugmaker was hit by U.S. supply issues for its new obesity drug as it seeks to establish a market foothold before the launch of a rival drug by Eli Lilly.
Who owns Ozempic?
Novo Nordisk has achieved strong sales figures for Ozempic (semaglutide), the injectable glucagon-like peptide-1 receptor agonist (GLP-1RA) indicated for the treatment of type two diabetes (T2D).
Who makes Ozempic?
Novo Nordisk is here to help you get your patients started on Ozempic®. We offer tools to help you check patient coverage and benefits. If eligible, commercially insured patients will receive a Savings Card to help make Ozempic® more affordable.
Is Novo Nordisk A Fortune 100 company?
Celebrating 12 Years as one of Fortune's “100 Best Companies to Work For” | Novo Nordisk U.S. Perspectives Blog.
Is Novo Nordisk Fortune 500?
The health care company is currently working to use artificial intelligence and robotics to improve patient care....Company Info.Rank last year90Job openings (as of February 2020)-IndustryBiotechnology & PharmaceuticalsRevenue, 2019 or most recent year ($M)$8,620Year founded19826 more rows
Who owns Novo Nordisk?
Novo Nordisk Foundation owns Novo Holdings A/S, a holding company that is the majority shareholder of Novo Nordisk, a Danish pharmaceutical corporation. From 2010 to 2015, the foundation distributed more than US$1.3 billion for research, innovation, treatment, education and humanitarian and social purposes.
Should I buy or sell Novo Nordisk A/S stock right now?
18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently...
What is Novo Nordisk A/S's stock price forecast for 2022?
18 analysts have issued 12 month price objectives for Novo Nordisk A/S's shares. Their forecasts range from $130.00 to $900.00. On average, they ex...
How has Novo Nordisk A/S's stock price performed in 2022?
Novo Nordisk A/S's stock was trading at $112.00 at the beginning of 2022. Since then, NVO stock has decreased by 0.5% and is now trading at $111.49...
Are investors shorting Novo Nordisk A/S?
Novo Nordisk A/S saw a drop in short interest in May. As of May 31st, there was short interest totaling 1,710,000 shares, a drop of 29.0% from the...
When is Novo Nordisk A/S's next earnings date?
Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for No...
How were Novo Nordisk A/S's earnings last quarter?
Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings data on Friday, April, 29th. The company reported $0.94 EPS for the quarter, beating t...
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?
Novo Nordisk A/S declared a Semi-Annual dividend on Wednesday, March 2nd. Shareholders of record on Monday, March 28th will be paid a dividend of $...
Is Novo Nordisk A/S a good dividend stock?
Novo Nordisk A/S(NYSE:NVO) pays an annual dividend of $1.48 per share and currently has a dividend yield of 1.33%. The dividend payout ratio of Nov...
Who are Novo Nordisk A/S's key executives?
Novo Nordisk A/S's management team includes the following people: Mr. Lars Fruergaard Jorgensen , Pres, CEO & Member of Management Board (Age 56...
How much does Novo Nordisk make?
Does Novo Nordisk have a dividend?
How much money does Novo Nordisk A/S make? Novo Nordisk A/S has a market capitalization of $210.21 billion and generates $19.45 billion in revenue each year. The company earns $6.46 billion in net income (profit) each year or $2.76 on an earnings per share basis.
Who owns Novo Nordisk?
Novo Nordisk A/S does not yet have a strong track record of dividend growth. The dividend payout ratio of Novo Nordisk A/S is 48.19%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 39.58% next year. This indicates that Novo Nordisk A/S will be able ...
What is the Novo Nordisk logo?
Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services specifically diabetes care medications and devices.
Where is Novo Nordisk headquartered?
The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations. Wikipedia. CEO. Lars Fruergaard Jørgensen.
How many people does Novo Nordisk employ?
Reported on 5/4/21. Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 5 countries.
What is Novo Nordisk?
Novo Nordisk employs more than 40,000 people globally, and markets its products in 180 countries. The corporation was created in 1989 through a merger of two Danish companies which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt.
Where is Novo Nordisk headquartered?
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm.
Is Novo Nordisk listed on the NYSE?
to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More... Sector.
New York Stock Exchange
Novo Nordisk A/S is currently listed on NYSE under NVO. One share of NVO stock can currently be purchased for approximately $ 89.65.
Environmental, Social, and Governance Rating
Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
How long are futures trading delayed?
Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.
How to calculate restricted stock?
Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle.
What is market capitalization for companies?
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
What is Novo Nordisk?
For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding. Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public. Public Float.
What is the name of the drug that Novo Nordisk makes?
Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity. Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals.
